Nuo Therapeutics 8K Regulation FD Disclosure | AURX 6 Jun 16

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MONTHLY OPERATING REPORT^*

Required Documents	Form No.	Document Attached	Explanation Attached	Affidavit or Supplement Attached
Schedule of Cash Receipts and Disbursements	MOR-1	ü
Bank Reconciliation (or copies of debtor's bank reconciliations)	MOR-1a	ü		ü
Schedule of Professional Fees Paid	MOR-1b	ü
Copies of bank statements				ü
Cash disbursements journals				ü
Statement of Operations	MOR-2	ü		ü
Balance Sheet	MOR-3	ü
Status of Postpetition Taxes	MOR-4	ü		ü
Copies of IRS Form 6123 or payment receipt				ü
Copies of tax returns filed during reporting period				ü
Summary of Unpaid Postpetition Debts	MOR-4	ü
Listing of aged accounts payable	MOR-4		ü
Accounts Receivable Reconciliation and Aging	MOR-5	ü
Debtor Questionnaire	MOR-5	ü

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

/s/ David E. Jorden			June 3, 2016
Signature of authorized individual			Date

David E. Jorden			Acting CEO and Acting CFO
Printed name of authorized individual			Title of authorized individual

* The information contained herein is provided as required by the Office of the United States Trustee. This Monthly Operating Report has been prepared based on information available to the Debtor as of the ending date in the reporting period shown above, and such information may be incomplete in certain respects. All information contained herein is unaudited and subject to future adjustments, which could be material. Nothing contained in this Monthly Operating Report shall constitute a waiver of any of the Debtor's rights or an admission with respect to its Chapter 11 proceedings. The Debtor reserves all rights to amend, modify or supplement this Monthly Operating Report.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-1

SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS¹

	BANK ACCOUNTS												CURRENT PERIOD				FILING TO DATE
	Business checking (Capital One)		Business money market (Capital One)		Certificate of deposit (Capital One)		Business money market (Capital One)		Business checking Class 4 (Capital One)		Cash reserves (Fidelity)		ACTUAL		PROJECTED²		ACTUAL		PROJECTED³
Account number ending in	0542		9462		4101		6936		3928		2370
Beginning cash balance		679,991		361		53,427		-		-		0		733,779		634,435		91,158		91,158

RECEIPTS
Revenue collections		290,750		-		-		-		-		-		290,750		164,800		553,470		427,520
Loans and advances		3,250,000		-		-		-		-		-		3,250,000		3,250,000		5,750,000		5,750,000
Sweeps from / (to) other accounts		-		-		-		-		-		-		-		-		-		-
Transfers from other accounts		-		-		-		-		-		-		-		-		-		-
Proceeds from sale of assets		-		-		-		-		-		-		-		-		-		-
Proceeds from capital raise		-		-		-		5,212,375		2,250,250		-		7,462,625		-		7,462,625		-
Other collections		-		0		-		-		-		-		0		-		6,199		6,199

TOTAL RECEIPTS		3,540,750		0		-		5,212,375		2,250,250		-		11,003,375		3,414,800		13,772,294		6,183,719

DISBURSEMENTS
Payroll and payroll taxes		237,226		-		-		-		-		-		237,226		235,553		578,912		811,347
Sales commissions		-		-		-		-		-		-		-		30,000		13,730		64,410
Employee benefits		5,757		-		-		-		-		-		5,757		44,643		38,210		105,994
Employee travel and entertainment		28,941		-		-		-		-		-		28,941		53,789		55,291		99,710
Research and development services		530		-		-		-		-		-		530		52,577		530		52,577
Inventory purchases		22,251		-		-		-		-		-		22,251		66,136		30,835		152,026
Outside services		13,626		-		-		-		-		-		13,626		22,435		24,156		48,602
Marketing expense		14,860		-		-		-		-		-		14,860		61,323		14,860		61,323
Reimbursement expense		19,300		-		-		-		-		-		19,300		52,896		19,300		55,757
Investor relations		550		-		-		-		-		-		550		7,801		550		9,083
Insurances		-		-		-		-		-		-		-		-		47,187		62,675
Information technology		36,414		-		-		-		-		-		36,414		8,957		36,414		65,255
Supplies		-		-		-		-		-		-		-		24,302		-		24,302
Utilities		4,366		-		-		-		-		-		4,366		3,245		4,526		11,697
Licensing fees		900		-		-		-		-		-		900		3,069		900		3,940
Professional fees, ordinary course		31,097		-		-		-		-		-		31,097		72,378		31,097		94,826
Board of Directors fees		48,737		-		-		-		-		-		48,737		17,425		48,737		17,425
Excise taxes		-		-		-		-		-		-		-		20,935		5,692		26,628
All other operating disbursements		160,503		-		-		-		-		-		160,503		73,426		187,824		249,891
Bank fees		1,384		-		-		-		-		-		1,384		5,000		1,969		6,216
Income and business taxes		20,650		-		-		-		-		-		20,650		29,570		29,543		41,729
Interest, DIP loan new money		78,822		-		-		-		-		-		78,822		32,885		78,822		32,885
Interest, DIP loan pre-petition roll-up		-		-		-		-		-		-		-		-		-		-
Fees, DIP loan		-		-		-		-		-		-		-		-		67,500		67,500
Professional fees, restructuring		579,375		-		-		-		-		-		579,375		448,187		749,376		1,011,177
U.S. Trustee fees		9,750		-		-		-		-		-		9,750		9,750		9,750		9,750
Transaction fees		-		-		-		-		-		-		-		-		-		-
Vendor deposits		15,000		-		-		-		-		-		15,000		15,000		45,000		70,000
Critical-vendor payments		36,774		-		-		-		-		-		36,774		66,294		263,265		426,491
Priority claims		-		-		-		-		-		-		-		-		-		-
KEIP/KERP		-		-		-		-		-		-		-		-		-		-
All other (sources) / uses		-		-		-		-		-		-		-		-		-		-
Transfers to other accounts		-		-		-		-		-		-		-		-		-		-

TOTAL DISBURSEMENTS		1,366,811		-		-		-		-		-		1,366,811		1,457,575		2,383,976		3,683,216

NET CASH FLOW		2,173,939		0		-		5,212,375		2,250,250		-		9,636,564		1,957,225		11,388,317		2,500,503

Ending cash balance	$	2,853,930	$	362	$	53,427	$	5,212,375	$	2,250,250	$	0	$	10,370,343	$	2,591,660	$	11,479,475	$	2,591,660

DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES
TOTAL DISBURSEMENTS (April 1, 2016 through May 5, 2016)			1,366,811
SUBTRACT: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS			0
ADD: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES (i.e. from escrow accounts)			0
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES			1,366,811

1. The accounting systems are not primarily designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in the cash flow are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. The figures in the Projected column reflect the DIP Budget exhibited in the Notice of Filing of Revised Budget entered on April 24, 2016.

3. The figures in the Projected column reflect the sum of actual results from the filing to date through March 31, 2016, and the DIP Budget exhibited in the Notice of Filing of Revised Budget as mentioned above from April 1 through May 5, 2016.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-1a

BANK ACCOUNTS¹

Bank name	Account type	Account number	Period-end bank balance
Capital One Bank (USA) N.A.	Business checking	ending in 0542		2,942,432.12
Capital One Bank (USA) N.A.	Business money market	ending in 9462		361.54
Capital One Bank (USA) N.A.	Certificate of deposit for Maryland Board of Pharmacy	ending in 4101		53,462.87
Capital One Bank (USA) N.A.	Business money market	ending in 6936		5,212,375.00
Capital One Bank (USA) N.A.	Business checking - Class 4 account	ending in 6928		2,250,250.00
FMR LLC (Fidelity)²	Cash reserves	ending in 2370		0.15

TOTAL BANK BALANCE				10,458,881.68

1. An attestation regarding the Debtor's bank statements and bank-account reconciliations follows this schedule.

2. In accordance with the request of the Office of the United States Trustee, the Debtor requested this account to be closed on Tuesday, March 8, 2016.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-1a

ATTESTATION REGARDING BANK ACCOUNTS

The above-captioned Debtor hereby submits this attestation regarding disbursement journals and bank-account reconciliations in lieu of providing copies of bank statements and account reconciliations.

I attest that each of the bank accounts listed in the preceding schedule is reconciled to monthly bank statements. The Debtor's standard practice is to ensure that each bank account is reconciled to monthly bank statements for each calendar month within 20 days after month end.

/s/ David E. Jorden		June 3, 2016
Signature of authorized individual		Date

David E. Jorden		Acting CEO and Acting CFO
Printed name of authorized individual		Title of authorized individual

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-1b

SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

This schedule is to include all retained professional payments from case inception to current month.

			Amount			Check			Period amount paid				Case-to-date amount paid
Payee	Period covered		approved		Payor	#/EFT		Date paid	Fees		Expenses		Fees		Expenses
Winter Harbor LLC		3/28/16 - 4/3/16		28,551.19	Nuo Therapeutics, Inc.		EFT	4/8/2016		26,289.00		2,262.19
Winter Harbor LLC		4/4/16 - 4/10/16		9,287.28	Nuo Therapeutics, Inc.		EFT	4/12/2016		8,149.00		1,138.28
Winter Harbor LLC		4/11/16 - 4/17/16		16,050.00	Nuo Therapeutics, Inc.		EFT	5/5/2016		14,757.00		1,293.00
Winter Harbor LLC		4/18/16 - 4/24/16		22,045.00	Nuo Therapeutics, Inc.		EFT	5/5/2016		19,724.50		2,320.50
Winter Harbor LLC		4/25/16 - 5/1/16		20,356.38	Nuo Therapeutics, Inc.		EFT	5/5/2016		17,816.50		2,539.88
				96,289.85						86,736.00		9,553.85		435,383.00		31,398.29

Dentons US LLP		1/26/16 - 2/29/16		268,298.40	Nuo Therapeutics, Inc.		EFT	4/22/2016		266,260.60		2,037.80		266,260.60		2,037.80


Ashby & Geddes, P.A.		1/26/16 - 2/29/16		76,072.39	Nuo Therapeutics, Inc.		EFT	4/13/2016		71,338.80		4,733.59		71,338.80		4,733.59

Gordian Group, LLC		1/26/16 - 2/29/16		51,964.32	Nuo Therapeutics, Inc.		EFT	4/27/2016		50,000.00		1,964.32		50,000.00		1,964.32

Epiq Bankruptcy Solutions, LLC		3/1/16 - 3/31/16		61,660.00	Nuo Therapeutics, Inc.		EFT	4/13/2016		24,149.18		37,510.82		51,120.59		81,310.82

Pepper Hamilton LLP		None		-	Nuo Therapeutics, Inc.		None	None		-		-		-		-

Robbins, Salomon & Patt, Ltd.		None		-	Nuo Therapeutics, Inc.		None	None		-		-		-		-

				554,284.96						498,484.58		55,800.38		874,102.99		121,444.82

Professional	Role	Notes
Winter Harbor LLC	Debtor's Chief Restructuring Officer and additional personnel
Dentons US LLP	Debtor's counsel, lead
Ashby & Geddes, P.A.	Debtor's counsel, local
Gordian Group, LLC	Debtor's investment banker and related services
Epiq Bankruptcy Solutions, LLC	Debtor's noticing, claims and balloting agent
Pepper Hamilton LLP	Counsel to the Official Committee of Unsecured Creditors
Robbins, Salomon & Patt, Ltd.	Counsel to the Ad Hoc Equity Committee

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-2

STATEMENT OF OPERATIONS (UNAUDITED)¹

Line item	Current period			Filing to date

Revenue
Sales, Aurix		95,160			258,830
Sales, Angel		232,691			287,154
Royalties		165,016			462,379
License fees		38,940			111,411
Other sales		-			-

Total revenue		531,807			1,119,775

Cost of sales
Cost of goods sold, Aurix		50,024			168,818
Cost of goods sold, Angel		206,554			303,592
Cost of royalties		15,194			43,470
Cost of license fees		-			(313	)
Other cost of sales		70			8,559

Total cost of sales		271,842			524,126

Gross profit		259,965			595,649

Operating expenses
Employee compensation and benefits		641,064			1,271,053
Insurance		32,704			88,196
Rent		50,992			91,462
Travel and entertainment		54,023			90,426
Depreciation and amortization		45,096			129,035
Selling and marketing expense		9,460			76,819
Research and development expense		109,277			245,085
Professional fees		78,969			178,851
Board of Directors fees		15,417			48,737
Other operating expenses²		56,716			187,475

Total operating expenses		1,093,718			2,407,139

Operating profit		(833,753	)		(1,811,490	)

Non-operating expenses
Interest expense / (income)		266,245			774,036
Reorganization expense / (income)²		746,610			2,830,546
Loss / (gain) on asset disposal		-			-
Other non-operating expense / (income)		(2,527	)		(2,527	)
Income-tax expense		-			4,896

Total non-operating expenses		1,010,328			3,606,951

NET INCOME		(1,844,081	)		(5,418,441	)

1. The accounting systems are not primarily designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. See the continuation sheet following Schedule MOR-2 for additional detail regarding these line items.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-2 CONTINUATION SHEET

STATEMENT OF OPERATIONS (UNAUDITED)¹

Line item	Current period			Filing to date

Other operating expenses
Other services		918			1,344
Investor services		8,713			13,854
Information technology		14,653			42,774
Temporary labor		-			-
Repairs and maintenance		250			250
Supplies		703			1,242
Office expense		9,263			(5,471	)
State and local taxes		9,205			24,878
Business-development expense		-			-
Bad-debt expense		-			(5,535	)
Dues, subscriptions and fees		12,197			112,833
Miscellaneous expense		814			1,306

Total other operating expenses		56,716			187,475

Reorganization expense / (income)²
Professional fees, Debtor's Chief Restructuring Officer		82,536			480,085
Professional fees, Debtor's counsel, lead		503,714			1,280,458
Professional fees, Debtor's counsel, local		57,707			229,983
Professional fees, Debtor's investment banker and related services³		(105,000	)		6,826
Professional fees, Debtor's claims and noticing agent		99,195			231,627
Professional fees, DIP lender's counsel, lead and local		-			140,109
Professional fees, Unsecured Creditors' Committee counsel		52,208			310,208
Professional fees, Ad Hoc Equity Committee counsel		50,000			135,000
U.S. Trustee fees		6,250			16,250

Total reorganization expense		746,610			2,830,546

1. The accounting systems are not primarily designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in this schedule are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. Several of these expenses are estimated in the case where invoices have not been received.

3. The credit to this account represents post-petition accruals reclassified to the additional paid-in capital balance-sheet account.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-3

BALANCE SHEET (UNAUDITED)¹

Line item	Current period			As of petition date

ASSETS
Current assets
Cash and cash equivalents		10,370,343			94,558
Accounts receivable		671,249			1,237,057
Intercompany receivable		14,821,589			14,593,348
Other receivables		959,250			474,489
Inventory		187,152			254,764
Deposits		382,227			478,564
Prepaid expenses		566,856			727,665
Deferred costs, current portion		1,091,387			1,091,387

Total current assets		29,050,052			18,951,831

Property, plant and equipment²
Angel machines		225,493			225,493
Aurix centrifuges		924,970			924,970
Computer and office equipment		113,842			113,842
Furniture and fixtures		40,849			40,849
Production equipment		307,851			307,851
Leasehold improvements		32,131			32,131
Software		523,571			523,571
Less: Accumulated depreciation		(1,263,377	)		(1,119,749	)

Net property, plant and equipment		905,331			1,048,959

Other assets
Deferred costs, long-term portion		2,077,154			2,379,339
Investment, Aldagen²		31,753,381			31,753,381
Intangible assets, net of accumulated amortization²		1,756,177			1,830,059
Other long-term assets		18,361			11,986

Total other assets		35,605,073			35,974,765

TOTAL ASSETS		65,560,457			55,975,555

LIABILITIES AND OWNERS' EQUITY
Liabilities not subject to compromise
Accounts payable		1,803,929			-
Accrued compensation and benefits		411,749			-
Accrued expenses		890,409			-
Accrued taxes		42,243			-
Accrued interest		415			-
Customer deposits		95,610			-
Debtor-in-possession financing		5,750,000			-
Convertible debt, net of original issue discount		-			-
Deferred revenue		899,921			-
Derivative liabilities		-			-
Other long-term liabilities		377,222			-

Total liabilities not subject to compromise		10,271,499			-

Liabilities subject to compromise³
Accounts payable		1,363,431			2,293,463
Accrued compensation and benefits		880,158			950,283
Accrued expenses		964,404			735,733
Accrued taxes		5,243			50,352
Accrued interest		4,529,645			4,529,645
Customer deposits		-			329,145
Debtor-in-possession financing		-			-
Convertible debt, net of original issue discount		1,306,238			981,554
Deferred revenue		-			1,072,103
Derivative liabilities		2,597,930			2,597,930
Other long-term liabilities		-			207,892

Total liabilities subject to compromise		11,647,049			13,748,099

Shareholders' equity
Mezzanine equity		500,000			500,000
Common stock		405,427			405,427
Additional paid-in capital		132,811,951			125,979,057
Retained earnings / (losses), pre-petition³		(82,770,978	)		(84,657,028	)
Retained earnings / (losses), post-petition		(5,418,441	)		-

Total shareholders' equity		45,527,959			42,227,456

TOTAL LIABILITIES AND OWNERS' EQUITY		67,446,507			55,975,555

1. The accounting systems are not principally designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in this schedule are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited and subject to future adjustments.

2. With respect to the book value of property, plant and equipment, the subsections of Accounting Standards Codification 360-10 “Property, Plant, and Equipment—Overall” published by the Financial Accounting Standards Board related to impairment or disposal of long-lived assets mandate that long-lived assets, such as property, plant and equipment, and purchased intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Although an impairment test has not yet been performed for the fiscal year ended December 31, 2015, the Debtor expects an asset impairment could be required in one or more asset categories.

3. Pre-petition liabilities and retained earnings continue to be adjusted monthly based on actual pre-petition invoices received and reconciled post-petition.

In re Nuo Therapeutics, Inc.		Case No. 16-10192 (MFW)
Debtor		Reporting Period: April 1 - May 5, 2016

MOR-4

STATUS OF POST-PETITION TAXES

Line item	Beginning liability			Amount withheld, accrued, and expensed			Amount paid			Date paid	Check #, EFT, or Other	Ending liability

Employee-related taxes
Federal tax		71			76,866			(69,114	)	Various	Wire		7,823
State tax		17			8,807			(8,806	)	Various	Wire		18
City tax		0			46			(46	)	Various	Wire		0
School-district tax		0			42			(42	)	Various	Wire		0

Subtotal, employee-related taxes		88			85,761			(78,008	)				7,841

Income and business taxes
Sales tax		20,798			2,504			(531	)	Various	ACH		22,771
Franchise tax		12,608			6,774			-		None	None		19,382
Income tax		4,896			-			-		None	None		4,896
All other taxes		-			-			-		None	None		-

Subtotal, income and business taxes		38,302											47,049

Taxes included in accounts payable		6,189			992			(4,897	)	Various	ACH		2,284

TOTAL TAXES		44,579			96,031			(83,436	)				57,174

Less: Taxes included in accounts payable		(6,189	)		(992	)		4,897		Various	ACH		(2,284	)
Less: Taxes included in other long-term liabilities		(4,896	)		-			-		None	None		(4,896	)
Less: Taxes included in Accrued Compensation		-			(7,752	)		-		None	None		(7,752	)

TOTAL ACCRUED TAXES		33,494			87,287			(78,539	)				42,242

In re Nuo Therapeutics, Inc.		Case No. 16-10192 (MFW)
Debtor		Reporting Period: April 1 - May 5, 2016

MOR-4

ATTESTATION REGARDING STATUS OF POST-PETITION TAXES

The above-captioned Debtor hereby submits this attestation regarding the status of post-petition taxes in lieu of providing tax returns and detailed records of paid or unpaid taxes by type and entity.

I hereby certify, to the best of my knowledge, that: (1) all federal, state and local post-petition taxes and estimates due and owing for the period indicated above for the Debtor have been paid or that any remaining balance dues arede minimis; and (2) to the extent that tax returns have not been submitted, an extension has been either obtained or requested from the appropriate state or federal agency, or the Debtor is in the process of obtaining or requesting such extension from the appropriate state or federal agency.

/s/ David E. Jorden		June 3, 2016
Signature of authorized individual		Date

David E. Jorden		Acting CEO and Acting CFO
Printed name of authorized individual		Title of authorized individual

In re Nuo Therapeutics, Inc.		Case No. 16-10192 (MFW)
Debtor		Reporting Period: April 1 - May 5, 2016

MOR-4

STATUS OF UNPAID POST-PETITION DEBTS¹

	Days Outstanding
Line item	Current		1-30		31-60		61-90		91-120			Over 120		Totals
Accounts payable²		1,379,266		256,370		114,905		59,951		(6,564	)		-		1,803,929
Accrued compensation and benefits		411,749		-		-		-		-			-		411,749
Accrued expenses		890,409		-		-		-		-			-		890,409
Accrued taxes		42,243		-		-		-		-			-		42,243
Accrued interest		415		-		-		-		-			-		415
Customer deposits		95,610		-		-		-		-			-		95,610
Debtor-in-possession financing		5,750,000		-		-		-		-			-		5,750,000
Convertible debt, net of original issue discount		-		-		-		-		-			-		-
Deferred revenue		899,921		-		-		-		-			-		899,921
Derivative liabilities		-		-		-		-		-			-		-
Other long-term liabilities		377,222		-		-		-		-			-		377,222

Totals		9,846,836		256,370		114,905		59,951		(6,564	)		-		10,271,499

1. All information contained herein is unaudited and subject to future adjustments. Certain debts payable pursuant to orders of the Bankruptcy Court are reflected as current for the purposes of this schedule. All post-petition debts other than aged accounts payable are assumed to be current.

2. Amounts in this line item represent open and outstanding trade vendor invoices, aged based on invoice due date, that have been entered into the Debtor's accounts payable system. These amounts do not include any payables based on accruals for goods provided and/or services performed but for which invoices have not been received. The Debtor expects to pay all amounts not listed as "Current" as soon as practicable. This note is provided in place of a list of aged accounts payable.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-5

ACCOUNTS RECEIVABLE RECONCILIATION AND AGING^*

	Days Outstanding
Line item	Current			1-30			31-60			61-90			Over 90			Totals
Accounts receivable		417,105			21,571			(17,801	)		175,579			154,981			751,435
Less: Allowance for doubtful accounts		-			-			-			-			(80,186	)		(80,186	)

Totals		417,105			21,571			(17,801	)		175,579			74,795			671,249
		62.1	%		3.2	%		-2.7	%		26.2	%		11.1	%		100.0	%

Reconciliation of accounts receivable, trade
Accounts receivable, net at the beginning of the reporting period																	836,717
Add: Amounts billed during the period																	390,114
Subtract: Amounts collected during the period																	(555,583	)
Subtract: Change in allowance for doubtful accounts																	0
Other adjustments																	0

Accounts receivable at the end of the reporting period																	671,249

* All information contained herein is unaudited and subject to future adjustments.

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: April 1 - May 5, 2016

MOR-5a

DEBTOR QUESTIONNAIRE

#	Line item	Yes	No
1	Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.	ü

2	Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.		ü

3	Have all post-petition tax returns been timely filed? If no, provide an explanation below.		ü

4	Are workers' compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.	ü

5	Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s).	ü

Explanations
1		On May 5, 2016, per the Notice of (I) Entry of Confirmation Order (A) Granting Final Approval of Disclosure Statement and (B) Confirming the Debtor's Modified First Amended Plan of Reorganization of the Debtor, (II) Occurrence of Effective Date, and (III) Rejection Claim Bar Date entered on May 6, 2016 [Docket No. 390], the Debtor's Plan of Reorganization was substantially consummated.

2		None required

3		The company has filed most of its tax returns timely, and the remaining returns are either in the process of being filed or were already filed but require corrections. The amounts potentially owed as a result of the latter category of returns are expected to bede minimis and will be paid as soon as practicable.

4		None required

5		Two bank accounts were opened with Capital One Bank (USA) N.A.: one ending in 6936 established as an escrow account containing proceeds from the Debtor's capital raise in conjunction with Scenario A of its confirmed Plan of Reorganization, less $2,250,250.00 segregated to pay Class 4 claims under the Plan of Reorganization ("Segregated Amount"); and one ending in 3928 containing the Segregated Amount. The documents related to these accounts follow this schedule.

Nuo Therapeutics (AURX) 8-KRegulation FD Disclosure